Gimeracil and Impurities
Ref: 4Z-G-047016
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047025
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047013
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047006
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047015
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047008
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047028
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047022
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Ref: 4Z-G-047029
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 25 Nov 2024
Gimeracil-13C3
Controlled ProductCAS:1184979-29-0
Applications Antitumor agent. A potent inhibitor of dihydropyrimidine dehydrogenase (DPD). References Shirasaka, T., et al.: …
Formula:
C213C3H4ClNO2
Color and Shape:
Neat
Molecular weight:
148.52
Ref: TR-G378002
5mg | 4,583.00 € | ||
500µg | 608.00 € |
Estimated delivery in United States, on Friday 29 Nov 2024
Ref: 4Z-G-047019
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information |